Overview

Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL

Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The standard of care therapy for DLBCL in the relapsed setting is RICE with the plan for the patient to proceed to transplant. This protocol will add Revlimid to the first 7 days of the RICE therapy and again after transplant as maintenance. To improve over all outcome and survival. Hypothesis is that combining lenalidomide with standard of care (RICE) may increase overall response rate thus increasing the number of patients able to proceed with autologous stem cell transplant. This in turn may translate into improved overall survival and progression free survival.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hackensack Meridian Health
Hackensack University Medical Center
Collaborator:
Celgene Corporation
Treatments:
Ifosfamide
Lenalidomide
Thalidomide